Drugs / 4SCAR19U
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05995015 | Jun 2026 → Dec 2029 expected | B-cell neoplasm | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 4SCAR19U | “The purpose of this study is to assess the feasibility, safety and efficacy of universal CAR T cell therapy against CD19-positive hematological malignancies using a novel...” NCT05995015 ↗ |
| Known as | 4SCAR19U cells | “Infusion of 4SCAR19U cells” NCT05995015 ↗ |
| Known as | 4SCAR19U T cells | “The purpose of this study is to assess the feasibility, safety and efficacy of universal CAR T cell therapy against CD19-positive hematological malignancies using a novel...” NCT05995015 ↗ |
| Modality | Cell therapy | “CAR T cell therapy” NCT05995015 ↗ |
| Target | CD19 | “CD19-specific CAR T cell product” NCT05995015 ↗ |